The Top Line

Fierce Life Sciences
  • 3.7（7則評分）
  • 商業新聞
  • 每週更新
The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

  1. 6 天前

    Misconduct and the future of neurodegenerative disease research

    Last month, the NIH announced that it had found evidence of research misconduct by Eliezer Masliah, M.D., the head of the neuroscience division at the National Institute on Aging. The NIH announcement coincided with the Sept. 26 publication of an investigation by Science, finding that 132 papers published by Masliah appear to contain manipulated images.  In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorvaia dives into this issue with Matthew Schrag, M.D., Ph.D., a neuroscientist who contributed to the dossier outlining Masliah’s misconduct. To learn more about the topics in this episode:   NIH neuroscience leader committed research misconduct, agency investigation finds See omnystudio.com/listener for privacy information.

    15 分鐘

  2. 11月8日

    Dig into this year’s Fierce Biotech Graveyard, layoff numbers

    Each year, we dive into the world of biotech closures and layoffs, tracking the industry’s pulse as companies navigate high risks and harsh realities.  In this week's episode of "The Top Line," Fierce editors Gabrielle Masson and Andrea Park take a closer look at this year’s biotech graveyard, which tracks biotechs that have shuttered or are in the process of winding down.   They also discuss how we identify these closures, the trends we’re seeing and what might be in store as the year wraps up.   To learn more about the topics in this episode:  The 2024 Biotech Graveyard Fierce Biotech Layoff Tracker 2024 See omnystudio.com/listener for privacy information.

    12 分鐘

  3. 11月1日

    Drug pricing and the 2024 presidential election

    As the 2024 U.S. presidential election nears, the choice between Democratic nominee Vice President Kamala Harris and Republican nominee former President Donald Trump will shape the future of drug pricing policy.   While both candidates have pledged to reduce drug costs, their approaches are likely to differ significantly.   In this week's episode of "The Top Line," Fierce Pharma's Zoey Becker chats with John Barkett, managing director of BRG’s healthcare transactions and strategy practice and former senior policy advisor for healthcare delivery system reform on the White House Domestic Policy Council, about what we can expect from each candidate's potential presidency and how the Inflation Reduction Act could play a pivotal role.   To learn more about the topics in this episode:  With election nearing, BMO analysts don't expect major pharma shake-ups from either candidate Biden touts drug pricing achievements as he steps down from reelection campaign 2024 forecast: Biden admin efforts show there's no pricing relief on the horizon for pharma See omnystudio.com/listener for privacy information.

    17 分鐘
  4. Discover Turbine’s way to build avatars true to patient biology [Sponsored]

    10月28日

    Discover Turbine’s way to build avatars true to patient biology [Sponsored]

    Explore how Turbine AI is revolutionizing drug development by tackling biases in data for more effective cancer treatments.

    18 分鐘

  5. 10月25日

    The pulse of the medtech industry

    EY recently published their 18th annual Pulse of the MedTech Industry report, highlighting how—despite steadily rising profits year-over-year—devicemakers large and small are still being squeezed by the cost of doing business and waning investor enthusiasm.   During AdvaMed’s MedTech Conference this month in Toronto, John Babbitt, partner on the life sciences team at EY, chatted with Fierce Medtech’s Conor Hale about the team's findings and shared what he heard from other executive attendees on the pace of M&A, venture capital funding and recent IPOs.   Babbitt also discussed how the industry is expanding over-the-counter, to stock shelves with consumer-focused products—as well as how a record number of AI approvals from the FDA may be counted on to help address the ever-growing demand for healthcare, amid provider burnout and staff shortages.  To learn more about the topics in this episode:  Ceribell CEO Jane Chao explains why now was the time for its upsized IPO Stryker strikes again, acquiring brain surgery device maker Nico How will regulators adapt to adaptive AI? Medtech VC investment held steady in Q2 with $3.3B of deal value: PitchBook EY's Pulse of the MedTech Industry report 2024 See omnystudio.com/listener for privacy information.

    20 分鐘

  6. 10月18日

    Where are they now? Catching up with past Fierce 15 honorees

    At this year’s Fierce Biotech Summit in Boston, we caught up with leaders in the biotech industry who have been recognized as past Fierce 15 honorees.  These private biotechs have made significant contributions to their field, and their groundbreaking work is shaping the industry's future. Fierce Biotech’s Gabrielle Masson sat down with Liang Schweizer, Ph.D. founder, chairperson and CEO of HiFiBiO Therapeutics; Adam Friedman, M.D., Ph.D., CEO of Scorpion Therapeutics; and Debanjan Ray CEO of Synthekine.  In this week’s episode of “The Top Line,” these leaders share their insights, experiences, and visions for the evolving biotech landscape. To learn more about the topics in this episode:  Introducing Fierce Biotech's 2024 Fierce 15 Scorpion snaps up $150M in series C funds to widen clinical plans for cancer pipeline Synthekine hopes new IL-2 will be the high-alpha in a beta class  See omnystudio.com/listener for privacy information.

    33 分鐘
  7. Revolutionizing gene therapy logistics with Cryoport's Elite solution [Sponsored]

    10月14日

    Revolutionizing gene therapy logistics with Cryoport's Elite solution [Sponsored]

    Cryoport Systems unveils its Elite Ultra Cold shipping system, which is designed to address critical needs in gene therapy transportation.

    24 分鐘

  8. 10月11日

    A revival in neuro therapeutics

    The neuroscience sector has seen a surge in investment over the past year, leading to breakthroughs and high-stakes deals, especially in the closing months of 2023. This momentum shows no signs of slowing, as companies continue to push boundaries in neuroscience and psychiatric disease research. At this year's Fierce Biotech Summit on Oct. 1, pharma staff writer, Fraiser Kansteiner, sat down with a panel of industry leaders to explore the latest trends, groundbreaking discoveries and the next big targets in neuropharmaceuticals. Joining the conversation were Camille Bendrosian, M.D., chief medical officer at Amylyx; Craig Thompson, CEO of Cerevance; Sara Kenkare-Mitra, Ph.D., president and head of R&D at Alector; and Blake Mandell, co-founder and CEO of Transcend Therapeutics.  To learn more about the topics in this episode:  Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy PTSD treatment is on the cusp of a paradigm shift. This biotech hopes to Transcend the competition After 'clearing the decks,' Alkermes ready to roll as pure-play neuroscience company Merck is back in Alzheimer's saddle with $1B-plus Cerevance pact, years after dropping the BACE See omnystudio.com/listener for privacy information.

    40 分鐘
顯示全部 (100)

評分與評論

3.7
（滿分 5 顆星）
7 則評分

簡介

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

資訊

  • 創作者
    Fierce Life Sciences
  • 活躍年代
    2023年 - 2024年
  • 集數
    100
  • 年齡分級
    兒少適宜
  • 節目網站
    The Top Line

你可能也會喜歡

若要收聽兒少不宜的單集，請登入帳號。

隨時掌握此節目最新消息

登入或註冊後，即可追蹤節目、儲存單集和掌握最新資訊。
選取國家或地區

非洲、中東和印度

亞太地區

歐洲

拉丁美洲與加勒比海地區

美國與加拿大